Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pipeline Watch: A New Era

Scrip’s popular Pipeline Watch feature has been updated to provide you with more analysis

READ NOW


Featured Stories


Rising Tide Lifts Many Ships In Wake Of Eisai/Biogen’s Lecanemab Readout

Eisai and Biogen had double-digit stock price gains based on the positive Phase III readout for lecanemab. The good news also lifted competitors Lilly and Roche as well as earlier-stage Alzheimer’s drug developers.

Clinical Trials Neurology Strategy

Pharming’s Leniolisib On Track To Become First Disease-Modifying APDS Drug

The Dutch firm’s US filing for its first-in-class PI3K inhibitor has been accepted under priority review, bringing the asset closer to becoming the first disease-modifying option for a rare, genetic disorder.

Drug Review Companies Rare Diseases

Regenxbio: On The Cusp Of Becoming A Commercial Gene Therapy Player

Partnered with AbbVie on a wet AMD gene therapy, Regenxbio is also advancing wholly owned candidates for Duchenne muscular dystrophy and MPS I and MPS II.

Gene Therapy Business Strategies Companies

Asia Spotlight

US-China Decoupling Gets On Biotech's Nerves

The Biden Administration’s latest Executive Order is aimed at shoring up investment in the US and securing supply chains for pharma and biotech products and is already impacting China's CDMO sector, but the long-term impact may be more nuanced, experts predict.

Supply Chain Policy

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D,

deal-making and business strategy developments.

More Podcasts


Recent Tweets from Scrip


 

Infographics

The Deal Landscape At Mid-Year: Is Industry Following Through On Business Development Promises?

INFOGRAPHIC: Going into 2022, there were high expectations for deal-making, but industry continues to face significant headwinds. Scrip reviewed M&A and alliance activity for the first half of the year to track how business development is shaping up in 2022. 

Deals M & A

Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again

Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.

Companies Leadership

COVID-19 Vaccine Pediatric Landscape In India - Biological E Scores, Zydus At Zero

India’s COVID-19 immunization focus has shifted to children as over 88% adults are fully vaccinated. However, Scrip’s examination of weekly data reveals the number of doses given to children are also dropping sharply off peaks. Meanwhile, Biological E is winning over others like Novavax in this segment while Zydus Lifesciences is yet to score

Commercial Coronavirus COVID-19

Commercial Explore this Topic

Set Alert for Commercial

Latest From Commercial

Pfizer Reveals Secret Digital Sauce To Cut Trial Duration, MLR Review Times

How do you send 90,000 employees home and still bring a COVID-19 vaccine to market in record time? Pfizer showed the way and at a recent virtual event, senior vice-president Robert Brown revealed how the "secret sauce" of digitalization continues to help cut medical legal review times, crunch clinical trial duration and reduce service interruptions.

Commercial Business Strategies

Pheon Hopes To Stir Up ADC Space With First-In-Class Compound

The UK firm with a presence in Boston has just emerged but Pheon’s CEO Bertrand Damour tells Scrip that big pharma is already showing interest in its next-generation antibody-drug conjugate.

Financing Cancer

Vertex/CRISPR Prepare To Take Exa-Cel To Regulators For SCD, TDT

The first gene-edited therapy will be submitted for sickle cell disease and transfusion-dependent beta thalassemia; it will compete with bluebird in both indications, but analysts anticipate blockbuster sales in excess of $2bn.

Gene Therapy Blood & Coagulation Disorders

Sanofi ThiNKs Scribe’s CRISPR Approach Can Advance Its NK Cell Therapy Goals

Deal Snapshot: CRISPR-Cas9 co-inventor Jennifer Doudna-founded gene-editing firm inks its second large collaboration, teaming with Sanofi on off-the-shelf natural killer cell therapies for cancer.

Deals Business Strategies

Boehringer Ingelheim’s Formula For Scaling Transformation, Digitization

Boehringer Ingelheim’s corporate senior vice president, head of global regions, Timmo Rousku Andersen, outlines at a recent summit the company’s reshaped approach to digital innovation and the need to entrench an execution bias to scale transformation initiatives.

Commercial Digital Health

Pharma Past Propels Julie Brown To GSK’s CFO Position

GSK has poached its new chief financial officer from fashion brand Burberry, but Julie Brown’s experience at AstraZeneca and Roche will give her insights into how to lead GSK into its next phase.

Executive Changes Leadership
See All

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Latest From Policy & Regulation

New Korean Accounting Guidelines Aim For More Flexible Biopharma Practices

South Korea moves to lay out clearer accounting guidelines related to R&D costs for pharma and biotech companies, making improvements to earlier official guidance in 2018 in order to ease uncertainties and help foster the sector.

South Korea Regulation

Amgen VP Encouraged By Initial Clinical Trial Diversity Efforts

Ponda Motsepe-Ditshego, who leads Amgen’s clinical trial diversity efforts, admits they are in early stages but noted progress internally and externally at better representing diverse patient groups.

Diversity & Inclusion Clinical Trials

Biogen Prepares More Doubtful Phase III Results For FDA Scrutiny, This Time In ALS

After the Aduhelm controversy, Biogen has another neurodegenerative disease drug which so far can only show efficacy against surrogate biomarkers – will the FDA be swayed again this time?

Clinical Trials Commercial
See All

Research & Development

Set Alert for Research & Development

Latest From Research & Development

Peptilogics’ AI Peptide Platform Could Help Address Orthopedic Unmet Need

Emerging Company Profile: US firm Peptilogics is advancing through the clinic with its lead orthopedic anti-infective drug candidate based on an AI platform that utilizes algorithms to improve peptide design.

Emerging Company Profile Orthopedics

A Banner Moment For Alzheimer's Positions Eisai/Biogen At The Head Of The Pack

Eisai and Biogen, who have an accelerated approval decision pending in the US, said they will seek traditional approvals for lecanemab by Q1 2023 based on positive results from the Phase III Clarity AD trial.

Clinical Trials Strategy

Stock Watch: Digging Holes And Clutching At Straws In Biotech R&D

Biotech CEOs often express surprise when the FDA rejects their drugs. But collaborative interactions between regulators and drug sponsors count for little if the latter fail to adjust their clinical and regulatory efforts accordingly.

Stock Watch Complete Response Letters
See All
UsernamePublicRestriction

Register